Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Cash & Equivalents (2020 - 2024)

Historic Cash & Equivalents for Universe Pharmaceuticals (UPC) over the last 6 years, with Q3 2025 value amounting to $29.5 billion.

  • Universe Pharmaceuticals' Cash & Equivalents changed 0.0% to $29.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $29.5 billion, marking a year-over-year change of 0.0%. This contributed to the annual value of $29.5 billion for FY2025, which is 45811.38% up from last year.
  • Per Universe Pharmaceuticals' latest filing, its Cash & Equivalents stood at $29.5 billion for Q3 2025, which was down 0.0% from $29.5 billion recorded in Q3 2024.
  • In the past 5 years, Universe Pharmaceuticals' Cash & Equivalents registered a high of $29.5 billion during Q3 2024, and its lowest value of $5.7 million during Q1 2023.
  • Its 5-year average for Cash & Equivalents is $8.8 billion, with a median of $2.6 billion in 2022.
  • In the last 5 years, Universe Pharmaceuticals' Cash & Equivalents skyrocketed by 7060466.76% in 2022 and then plummeted by 5988.1% in 2023.
  • Universe Pharmaceuticals' Cash & Equivalents (Quarter) stood at $8.1 million in 2021, then surged by 70604.67% to $5.7 billion in 2022, then fell by 7.46% to $5.3 billion in 2023, then surged by 458.11% to $29.5 billion in 2024, then changed by 0.0% to $29.5 billion in 2025.
  • Its Cash & Equivalents stands at $29.5 billion for Q3 2025, versus $29.5 billion for Q3 2024 and $8.9 million for Q1 2024.